This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vearing, C. Articles by Lackmann, M. Search for Related Content PubMed PubMed Citation Articles by Vearing, C. Articles by Lackmann, M.

Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents

¹ Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia; ² Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia; ³ Leukemia Foundation Cancer Research Unit, Queensland Institute of Medical Research, P.O. Royal Brisbane Hospital, Brisbane, Queensland, Australia; and ⁴ Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Martin Lackmann, Department of Biochemistry and Molecular Biology, Monash University, P.O. Box 13D, Clayton, Victoria 3800, Australia. Phone: 61-3-9905-3738; Fax: 61-9905-3726; E-mail: Martin.Lackmann{at}med.monash.edu.au.

The Eph receptor tyrosine kinases and their membrane-bound ephrin ligands form a unique cell-cell contact–mediated system for controlling cell localization and organization. Their high expression in a wide variety of human tumors indicates a role in tumor progression, and relatively low Eph and ephrin levels in normal tissues make these proteins potential targets for anticancer therapies. The monoclonal antibody IIIA4, previously used to isolate EphA3, binds with subnanomolar affinity to a conformation-specific epitope within the ephrin-binding domain that is closely adjacent to the "low-affinity" ephrin-A5 heterotetramerization site. We show that similar to ephrin-A5, preclustered IIIA4 effectively triggers EphA3 activation, contraction of the cytoskeleton, and cell rounding. BIAcore analysis, immunoblot, and confocal microscopy of wild-type and mutant EphA3 with compromised ephrin-A5 or IIIA4-binding capacities indicate that IIIA4 binding triggers an EphA3 conformation which is permissive for the assembly of EphA3/ephrin-A5-type signaling clusters. Furthermore, unclustered IIIA4 and ephrin-A5 Fc applied in combination initiate greatly enhanced EphA3 signaling. Radiometal conjugates of ephrin-A5 and IIIA4 retain their affinity, and in mouse xenografts localize to, and are internalized rapidly into EphA3-positive, human tumors. These findings show the biological importance of EphA3/ephrin-A5 interactions and that ephrin-A5 and IIIA4 have great potential as tumor targeting reagents.

This article has been cited by other articles:

				T. Yamazaki, J. Masuda, T. Omori, R. Usui, H. Akiyama, and Y. Maru EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility J. Cell Sci., January 15, 2009; 122(2): 243 - 255. [Abstract] [Full Text] [PDF]

				S. H. Wimmer-Kleikamp, E. Nievergall, K. Gegenbauer, S. Adikari, M. Mansour, T. Yeadon, A. W. Boyd, N. R. Patani, and M. Lackmann Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells Blood, August 1, 2008; 112(3): 721 - 732. [Abstract] [Full Text] [PDF]